semaglutide and birth defects 🔹 New Human Reproduction Press Release🔹 Weight loss drugs have been linked to an increased risk of premature births among women who took them inadvertently just before or during early pregnancy to Why a 3,572-pregnancy study can't

Retatrutide Is a First-in-Its-Class Medication Retatrutide is a triple agonist medication, meaning it works on three different hormone receptors in the body: GLP-1, GIP, and glucagon leading some experts to call it a triple-G drug

Published November 27, 2023

When it comes to achieving that healthy glow, most of us think about external skincare routines serums, moisturizers, and treatments

Administered weekly at 2.4 mg subcutaneously, semaglutide has secured regulatory clearance in the United States, Europe, the United Kingdom, and Canada for weight management in adults grappling with overweight (BMI 27 kg m2 alongside at least one obesity-related comorbidity) or obesity (BMI 30 kg m2), backed by findings from the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trial program